No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. by Williams, K. J. et al.
Britsh Journal of Cancer (1996) 74, 698-703
©C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni
lymphoblastoid cell lines
KJ Williams', J Heighway', JM Birch2, JD Norton3 and D Scott'
'CRC Department of Cancer Genetics, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, M20
9BX, UK; 2CRC Paediatric and Familial Cancer Research Group, Christie Hospital NHS Trust, Manchester; 3CRC Department of
Gene Regulation, Paterson Institutefor Cancer Research, Christie Hospital NHS Trust, Manchester, M20 9BX, UK.
Summary The radiation response of Epstein-Barr virus (EBV)-immortalised lymphoblastoid cell lines derived
from Li-Fraumeni syndrome (LFS) and LFS-like individuals was investigated. Cells from all LFS and LFS-like
cases showed an accumulation ofp53 protein following 137Cs y-irradiation, which was associated with cell cycle
arrest at the G1/S border. This response was indistinguishable from that seen in cells derived from normal
individuals, and occurred in cases with missense mutations in the TP53 gene at codons 175, 180, 220 and 248,
and also in two LFS-like individuals with no TP53 mutation. Previous studies using lymphocytes and
fibroblasts from LFS individuals have demonstrated abnormal radiation responses in these cells. This suggests
cell type specificity in the contribution of a mutant p53 protein to phenotype.
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Li-Fraumeni Syndrome (LFS) describes a rare dominantly
inherited familial predisposition to neoplasms of diverse
tissue origin, usually with an early age of onset (Li and
Fraumeni, 1969). Typical cancers include sarcomas, preme-
nopausal breast carcinomas, brain tumours, leukaemias and
adrenocortical carcinomas. In most, but not all families,
cancer predisposition is associated with a germline mutation
in one allele of the TP53 gene (Malkin et al., 1990;
Santibaiinez-Koref et al., 1991; Birch et al., 1994), which
encodes the p53 tumour-suppressor protein.
The p53 protein is a transcriptionally active DNA-binding
protein involved in the cellular response to DNA damage.
The best characterised function of the protein is as a GI/S
checkpoint control for DNA damage (Kuerbitz et al., 1992),
where a temporal association between elevated p53 expres-
sion and cell cycle arrest at the G,/S border is observed
following treatment with agents that induce DNA double-
strand breaks (for example y-irradiation; Kastan et al., 1991).
The downstream effector molecule of the p53-dependent GQ/S
cell cycle arrest is p2lWaf/CIPI (El-Deiry et al., 1993). Induction
of this protein both prevents GQ/S phase transition via the
inhibition of cyclin-dependent kinase activity (Xiong et al.,
1993) and halts DNA replication by negative regulation of
proliferating cell nuclear antigen (PCNA) (Waga et al., 1994).
The resulting pause in cell cycle progression is thought to
allow time for DNA damage repair before DNA synthesis
and loss of G,/S checkpoint control may be associated with
increased heritable genetic abnormalities following DNA
damage (Lane, 1992).
O'Connor et al. (1993) have reported reduced GI/S arrest
capacity in Burkitt's lymphoma cell lines harbouring
heterozygous TP53 mutations at codons 158 and 248. In
our study we have utilised EBV-immortalised lymphoblastoid
cell lines (LCLs) derived from LFS individuals both with and
without heterozygous germline mutations in the TP53 gene.
The response of these cell lines to radiation-induced DNA
damage was ascertained in terms of p53 protein induction
and G1/S arrest.
Materials and methods
Patients and cell lines
Families from which cell lines were derived conformed either
to the classic definition of LFS: proband with sarcoma before
45 years of age, with at least one first-and one second-degree
relative with cancer before 45 years of age, or sarcoma at any
age; or to the broader definition (LFS-like): proband with
any childhood cancer or sarcoma, brain tumour or
adrenocortical carcinoma diagnosed under 45 years of age,
plus one first- or second-degree relative in the same lineage
with any cancer diagnosed under age 60 (Birch et al., 1994).
LFS and LFS-like LCLs were derived from blood samples
obtained through the CRC Paediatric and Familial Cancer
Research Group, Manchester. Control LCLs used in this
study were derived from normal, healthy donors. Cells were
maintained in RPMI-1640 with 20 mM Hepes, 2 mM
glutamine, 10% fetal calf serum (FCS), 0.2% (w/v) sodium
bicarbonate and 40 gg ml-' gentamicin at 37'C in a
humidified 95% air-5% carbon dioxide atmosphere. The
Burkitt's lymphoma line, Ramos, was cultured in RPMI with
2 mM glutamine, 10% FCS and 100 ,ug ml'- penicillin/
streptomycin in the above conditions. Details of the LFS
cell lines used are given in Table I.
Irradiation
Exponentially growing cells (3-5 x 105 ml-') were y-irra-
diated to a total dose of 6 Gy delivered at 3.34 Gy min-1 at
ambient temperature using a '37Cs source.
Gel electrophoresis and Western blotting
The immunoblotting procedure used was essentially that of
Kastan et al. (1992). Proteins from the lysate of 5 x 105 cells
and an internal control lysate of the MDA231 cell line, which
overexpresses p53, were separated on a 12.5% (w/v) sodium
dodecylsulphate polyacrylamide gel by electrophoresis (SDS-
PAGE) (Promega). Following Western transfer and blocking,
blots were incubated with PAbl801 (Ab-2, Oncogene
Science,), which recognises a denaturation-resistant epitope
between amino acids 32 and 79 ofp53, washed and incubated
with a horseradish peroxidase-conjugated secondary anti-
body. Protein detection was carried out using enhanced
chemiluminescence (ECL) according to manufacturers'
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Table I Details of cell lines used
p53 mutationsC
Cell linea Familyb Personc Family type Exon Codon Base change Amino acid change
Ramos NA NA NA 7 254 Ile-*Asp
Dd
MA120 16 011 LFS 6 220 TAT-TGT Tyr-*Cys
MA65 80 099 LFS-like No mutation found
MA62 80 163 LFS-like No mutation found
MA150 83 002 LFS 5 175 CGC-+CAC Arg-+His
MA008 83 004 LFS 5 175 CGC-+CAC Arg-.His
MA147 83 005 LFS 5 175 CGC-+CAC Arg-+His
CV139 84 035 LFS 7 248 CGG-+CAG Arg--Gln
MAIOI 85 001 LFS-like 5 180 GAG-+AAG Glu-+Lys
MA132 222 001 LFS 7 248 CGG-dCAG Arg-+Gln
aWith the exception of Ramos (EBV-negative Burkitt's lymphoma), all are EBV-immortalised LCLs. bFamily and
person numbers refer to pedigrees published in Birch et al. (1994). Cp53 status of LCLs was determined by direct
sequencing ofthe entire coding region ofthe TP53 gene (Birch et al., 1994). dD denotes deletion ofthe second allele in
this cell line.
instructions (Amersham Life Science), with the exposure of
blot to film standardised to the intensity of the internal
control band. Protein levels were determined visually from
band intensities. Equivalent protein transfer to the blots was
confirmed by staining with India ink (Harlow and Lane
1988). To analyse p53 protein induction following DNA
damage, lysates were prepared 4 h after irradiation of
exponentially growing cells at 6 Gy.
Flow cytometry
Cells were washed in ice-cold phosphate-buffered saline
(PBS), fixed by the dropwise addition of ice-cold 70% (v/v)
ethanol while vortex mixing, and maintained on ice for at
least 30 min. Following washing in ice-cold PBS, cells were
treated with RNAase (40 min at 37°C, 1 mg ml-1, Sigma)
and cellular DNA stained with propidium iodide (PI,
100 jug ml-1 in PBS) for 15 min on ice. Cell cycle
determination was performed using an EPICS fluorescence-
activated cell analyser, in which DNA content, as assayed by
PI staining, was used to distinguish cell cycle phase. For
analysis ofGI/S arrest following DNA damage, exponentially
growing cells were y-irradiated at 6 Gy and fixed 16 h after-
irradiation, before PI staining.
Metaphase preparations
Cells were partially synchronised by treating with thymidine
(300 jug ml- 1 culture) for 16 h, washed twice in medium
without thymidine and incubated for 5 h before the addition
of colcemid (0.1 tg ml-' culture) for 20 min. Cells were then
given a hypotonic treatment (0.075 M potassium chloride, 10-
15 min), fixed inmethanol-acetic acids (3: 1), stored at -20°C
then dispensed onto slides and stained with 2% Giemsa.
Polymerase chain reaction-restriction fragment length
polymophism (PCR-RFLP) analysis of loss ofheterozygosity
Loss of constitutional heterozygosity (LOH) at the TP53
locus was monitored by PCR-based RFLP analysis. DNA
was extracted from the cell lines, normal tissue and LFS
patient control blood samples by standard protocols. An
aliquot of 0.2 ,ug of genomic DNA was amplified in a 100 yl
reaction containing 0.5 jIg of each primer (forward/reverse),
1 x Taq polymerase reaction buffer (BCL), 250 guM dNTPs
(BCL) and 2.5 U of Taq polymerase. Following a 2 min
denaturation step at 94°C, reactions were cycled 30 times at
56°C for 1 min, 74°C for 1 min followed by 1 min at 55°C
and 3 min at 74°C. Primers used were as follows (Genbank
accession number X54156).
Forward aggcgcactggcctcatctt--+TP53 nucleotide 13960-
13979
Reverse gacctcgagtcttccagtgtg -. TP53 nucleotide 14112-
14092
PCR-generated fragments (0.5 ,g) from each sample were
digested for 2 h at 37°C, with 10 U of Mspl (Biolabs) in a
50 yl reaction and the products separated on 3% agarose
gels containing ethidium bromide (0.1 HIg ml-'). The relative
intensities of mutant and wild-type bands derived from the
cell line DNA samples were compared visually with each
other and with control (patient peripheral blood) digests.
Results
Immunoblotting techniques were employed to determine both
constitutive and radiation-induced p53 protein levels in all
cell lines utilised in this study. In the uninduced state, the
levels of p53 detected were heterogeneous (Figure la; Table
II), but were reproducible for each cell line in independent
experiments. The LFS-like cells with no p53 mutation
exhibited constitutive p53 expression within the range of
normal individuals. Of those cell lines with a germline p53
mutation, MA008 and CV139 (codon 175 and 248 TP53
mutations, respectively) expressed elevated p53 compared
with the normal LCLs. However, the significance of this
observation is not clear, because MA147 and MA150 (which
share the same TP53 mutation as MA008) and MA132
(which harbours the codon 248 TP53 mutation of CV139)
exhibited p53 expression within the range displayed by
normal cells. No cell line expressed constitutive p53 levels
as high as that observed in the Burkitt's lymphoma cell line,
Ramos.
Following y-irradiation of the control cell line SV21 at 6
Gy, increased p53 protein levels were observed within 2 h and
remained significantly higher than the constitutive level for at
least 8 h, with maximum expression occurring 4 h after
irradiation (Figure lb). This pattern of induction was also
seen in a second control cell line (data not shown). Based
upon these observations, radiation-induced p53 levels were
determined 4 h after irradiation in all further experiments. In
all control, LFS and LFS-like cells, an accumulation of p53
protein was observed after irradiation at 6 Gy (Figure lc
Table II). There appears to be no significant overall difference
between the induced levels of p53 seen in the normal, LFS
and LFS-like cells (Table II). No protein accumulation
following irradiation was seen in the Ramos cell line, as
previously reported by O'Connor et al. (1993).
Cell cycle progression following y-irradiation was exam-
ined using flow cytometry. Exponentially growing cells were
either untreated, or y-irradiated at 6 Gy and analysed 16 h
after irradiation. The dose and post-irradiation sampling time
were those used by O'Connor et al. (1993) and were
confirmed as optimal for use with the LCLs used in this
study (data not shown). The profiles obtained for a normal
cell line and for Ramos, which lacks functional p53 protein,
are depicted in Figure 2. In the normal cell line, competent
G, and G2 arrest occur. Hence, the G, population afterCell cycle arrest in Li-Fraumeni cells
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Figure 1 p53 expression in LCLs derived from normal, LFS and LFS-like individuals. Exponentially growing cells were lysed,
extracts electrophoresed, Western blotted, probed with PAbl801 (Oncogene Science) and protein detected using enhanced
chemiluminescence (Amersham). Lysate of the p53-overexpressing cell line MDA231 was included in each SDS-PAGE, and
exposure of blot to film in independent experiments was standardised to the band intensity of this internal control. (a) Constitutive
p53 levels. (b) Time course of p53 induction in the normal LCL, SV21, following y-irradiation at 6 Gy. Numbers indicate post-
irradiation time. (c) Representative examples of p53 induction 4h after irradiation.
Table H Constitutive and y-ray-induced p53 levels
pS3 expressiona
Cell line Type p53 status Constitutive Induced'
SV19 Normal ND + + + + +
SV21 Normal ND + + + + + +
SV27 Normal ND + + + + +
SV28 Normal ND + + + + +
MA42 Normal ND + + + + + + +
MA69 Normal ND + + +
MA120 LFS wt/mut + + + + + +
MA65 LFS-like wt/wt + + +
MA62 LFS-like wt/wt + + + + + +
MA150 LFS wt/mut + + + + + + +
MA008 LFS wt/mut + + + + + + + +
MA147 LFS wt/mut + + + + +
CV139 LFS wt/mut + + + + + + +
MAIOI LFS-like wt/mut + + + + + +
MA132 LFS wt/mut + + + + + +
Ramos BL mut/del + + + + + + + + + +
aEstimated from immunoblots from two independent experiments;
+ represents the lowest and + + + + + the highest expression
observed. bp53 levels in exponentially growing, untreated cells. Cp53
levels determined 4 h after y-irradiation at 6 Gy. ND, not determined;
BL, Burkitt's lymphoma.
irradiation is similar to that of the untreated sample and
those cells traversing S-phase during the post-irradiation
incubation period accumulate in G2 (Figure 2b). In contrast,
Ramos exhibits G2 arrest only. Thus, the G, population is
depleted after irradition and a shift towards the G2
compartment is seen (Figure 2d). A comparison between
the control and irradiated G1 population was made for each
of the cell lines used in this study. The data obtained are
presented in Figure 3, and clearly demonstrate that the LFS
and LFS-like cells exhibit competent GI arrest following
irradition, with minimal GI arrest being exhibited by Ramos.
To ensure that the G1 population after irradiation
represented cells arrested at this cell cycle stage, experiments
using representative cell lines were repeated in the presence of
the mitotic inhibitor nocodazole (0.4 ug ml-'), which blocks
cells in the G2/M phase ofcell cycle. This had no effect on the
percentage of cells remaining in GI after irradiation (data not
shown).
In the course of this study, a reduction in the G1 arrest
capacity of the LFS cell line, CV139 (codon 248 mutation)
was observed, which was associated with the cell line
having acquired a near tetraploid DNA content, as
analysed by flow cytometry. Early and late passage
CV139 cells were assayed for G1 arrest and p53
induction. Chromosome numbers were also determined
(Table III) and confirmed the flow cytometry measure-
ments. The change in GI arrest status was not associated
with a loss of p53 induction after y-irradiation (Table III).
To ascertain whether the change in phenotype could be
attributable to loss of the wild-type p53 allele, RFLP
analysis was carried out. As normal material was not
available from the individual from which CV139 was
derived, constitutional DNA isolated from peripheral
blood of another patient with a 248 mutation was used
as a normal/mutant control sample. The RFLP analysis
revealed no LOH in either the diploid or hypotetraploid
cell line (Figure 4). Indeed, the relative band intensity in
the hypotetraploid line indicated an overrepresentation of
the wild-type allele in those cells. In further experiments,
the late passage CV139 cells also displayed an enhanced
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Figure 2 Cell cycle progression following y-irradiation as determined by flow cytometry of propidium iodide-stained cells. Control
profiles (a and c) were obtained from exponentially growing, untreated cells and irradiated profiles (c and d) obtained 16h after
irradiation at 6 Gy. In the normal LCL, the proportion of cells remaining in G1 following irradiation (b) is similar to that in the
control (a). Minimal G1 arrest, exhibited by Ramos, is depicted in (c) and (d). Both samples displayed G2 arrest in response to
irradiation. (Propidium iodide fluorescence is given on the IRFL axis).
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growth rate and ability to form colonies in soft agar
together with enhanced survival and proliferation in low
serum-containing medium, compared with normal cell lines
(data not shown).
Discussion
Our data suggest that the presence of a heterozygous
mutation in the TP53 gene has no effect on radiation-
induced p53 protein expression and subsequent G,/S arrest in
LFS and LFS-like lymphoblastoid cell lines. LCLs derived
from LFS-like individuals where cancer predisposition is not
linked to the TP53 gene also exhibited a normal radiation
response.
The ability of a mutant p53 protein to interfere with wild-
type function may be dependent on the exact nature of the
mutation. Previous publications have shown some mutations
to have a dominant negative mode of action (Milner and
Medcalf, 1991; Miller et al., 1993; Srivastava ct af., 1993).
However, one such mutation is the Arg-175-*His mutation
harboured by MA008, MA147 and MA150 and shown to
have no effect on radiation-induced arrest in this study. There
appears to be a discrepancy between data presented here and
those of O'Connor et Cll. (1993), in which a Burkitt's
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lymphoma cell line with an Arg-248-Gln mutation was
shown to have a reduced capacity to arrest in G,. Two cell
lines used in this study, CV139 and MA132, also harbour this
mutation, but exhibit normal arrest. A possible explanation
lies in the ploidy of the cell lines. During prolonged culture,
CV139 became aneuploid, and this was associated with a
reduced capacity for G,/S arrest. Aneuploidy is common in
Burkitt's lymphoma cell lines, and indeed the second p53 wt/
mut cell line shown by O'Connor et al. (1993) to have
aberrant arrest was aneuploid (Magrath et al., 1980).
It is becoming increasingly apparent that phenotypic
effects attributable to the presence of a heterozygous TP53
mutation may be cell type specific. Dominant negative effects
of mutant p53 in LFS cells have been reported. A reduced
capacity for apoptosis in response to ,-irradiation has been
demonstrated in unstimulated LFS peripheral blood lympho-
cytes (Camplejohn et al., 1995). LFS fibroblasts have been
shown to be resistant to the lethal effects of ionising radiation
(Sproston ct al., 1996). Further data on LFS fibroblasts are
equivocal, with abnormal phenotypes (Bech-Hansen ct al.,
1981; Parshad ct al., 1993) not being associated with
mutation in TP53 in all family members (Srivastava ct al.,
1990). Also, the spontaneous immortalization of LFS
fibroblasts by Bischoff et al. (1990) was disputed by
Livingstone ct al. (1993). In this latter case, the discrepancy
may be due to loss of the wild-type allele. The apparently
normal radiation response of LFS cell lines described here is
supported by Lalle ct al. (1995), who recently documented
normal G, arrest in LCLs derived from LFS individuals with
codon 257 missense, codon 257 frameshift and codon 342
nonsense mutations. In addition, we have shown four further
missense mutations (codons 175, 180, 220 and 248), which do
not induce any change in G,/S arrest phenotype following -
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Figure 3 GI arrest in normal, LFS and LFS-like LCLs following
7-irradiation. Cells were irradiated at 6 Gy and the percentage of
cells remaining in G, 16 h post-irradiation determined. Data
presented is the mean of at least two observations, with standard
deviations indicated by error bars. (BLa Burkitt's lymphoma, p53
mut/del).
Figure 4 PCR-based RFLP analysis of DNA from the CV139
cell line (E,L), normal lung tissue (N) and LFS patient (248
mutation) peripheral blood sample (C). The position of wild-type
and mutant bands is indicated. Relative band intensity (wt/mut)
in the early passage CV139 cells (E) is similar to the constitutional
control ratio (C), indicating no LOH in this sample. In the late-
passage sample (L), the normal band appears to be stronger,
suggesting retention of the wild-type allele and overrepresentation
of the chromosome carrying the normal TP53 allele in the
hypotetraploid cell line.
Table III Altered characteristics of CV139 in long-term culture
p53 exvpression
Passage Caonstitutiveb Induced
Early
Late
GI arrest1 Clhr-omiiosomiie number'
% ( + .s.d.J Mo(le Range
+ + + + 79.2 (±2)
+ + + + 46.6 (+15)
46 41 -46
86 69 -89
a'bcSee footnotes to Table II.dG, arrest is given as percentage ofcells remaining in G1 at
16 h after irradiation (6 Gy). eTwenty-five metaphases scored.
aCU cyce rs i U-Fraunen ceds
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irradiation. including both a dominant negative mutation
(Arg-175-+His) and the most frequently mutated codon in
the TP53 gene (codon 248; Prives. 1994). As suggested by
Lalle et al. (1995) the cell type specificity of the contribution
of a heterozygous TP53 mutation to phenotype may account
for the specific range of neoplasms observed at high
frequency in LFS.
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